Genedata Biologics for Streamlined Protein Engineering at PEGS Europe

UCB Pharma and Genedata will showcase data management and workflow system that captures production and characterization data for biotherapeutics and reagents

Vienna, Austria, November 6, 2012

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced Genedata Biologics™ will be featured at the Fourth Annual PEGS Europe Protein & Antibody Engineering Summit. A first-in-class, end-to-end solution for biologics R&D, Genedata Biologics will be showcased at the PEGS session on “Enhancing Expression and Achieving Higher Throughput.” The session will detail UCB Pharma’s novel data management and workflow system based on Genedata Biologics and optimized for automation of high-throughput processes spanning molecular biology, expression, purification, and analytics. Co-presented by UCB Pharma and Genedata, the session will be held on November 7 (PEGS Europe Nov 6-8).

Recent advances in cell line development and automation technologies enable the parallel expression of large numbers of biomolecules. The collection, management, and interpretation of biologics data can be a time-consuming process that impedes efficient discovery and development of protein-based drugs. As an end-to-end data management system, Genedata Biologics addresses these inefficiencies. Collaborating with Genedata, No linkhandler TypoScript configuration found for key tt_news.. has further enhanced the Genedata Biologics system. Capabilities, which will be examined at PEGS, include:

  • Comprehensive workflow support and knowledge management for antibody discovery
  • Large-scale molecule generation via novel bulk in silico cloning tools
  • Sophisticated biologics molecule and sample management (e.g. material genealogy)
  • Integrated system for biotherapeutics and tool proteins (reagents)
  • Centralized data access for scientists across different sites and groups
  • Integration with corporate IT systems (i.e. humanization applications, ELN, etc.)


“We are continually innovating Genedata Biologics to support scientists in their daily research,” said Dr. Othmar Pfannes. “Our work with UCB underscores that innovation, which extends Genedata Biologics’ value beyond data management with enriched support for complex workflows, new technologies, and logistics.”
 
Editorial Note: November 6 at 9:35am CET, Genedata Biologics will be featured in the PEGS Europe Enhancing Expression and Achieving High Throughput Session: “No linkhandler TypoScript configuration found for key tt_news..” by David Lee, Ph.D. Principal Scientist/UCB Pharma and Maria Wendt, Ph.D., Scientific Consultant/Genedata. To schedule a briefing contact jackie.thrasivoulos@genedata.com.

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. www.genedata.com.

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.